FCX vs REGN · P/E 38, rev $25.45B vs P/E 14, rev $14.34B
Freeport-McMoran Copper & Gold Inc (FCX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the FCX and REGN stock pages for the full models.
Not investment advice.